Literature DB >> 19778568

The kynurenine pathway in adolescent depression: preliminary findings from a proton MR spectroscopy study.

Vilma Gabbay1, Leonard Liebes, Yisrael Katz, Songtao Liu, Sandra Mendoza, James S Babb, Rachel G Klein, Oded Gonen.   

Abstract

BACKGROUND: Cytokine induction of the enzyme indoleamine 2,3-dioxygenase (IDO) has been implicated in the development of major depressive disorder (MDD). IDO metabolizes tryptophan (TRP) into kynurenine (KYN), thereby decreasing TRP availability to the brain. KYN is further metabolized into several neurotoxins. The aims of this pilot were to examine possible relationships between plasma TRP, KYN, and 3-hydroxyanthranilic acid (3-HAA, neurotoxic metabolite) and striatal total choline (tCho, cell membrane turnover biomarker) in adolescents with MDD. We hypothesized that MDD adolescents would exhibit: i) positive correlations between KYN and 3-HAA and striatal tCho and a negative correlation between TRP and striatal tCho; and, ii) the anticipated correlations would be more pronounced in the melancholic subtype group.
METHODS: Fourteen adolescents with MDD (seven with melancholic features) and six healthy controls were enrolled. Minimums of 6 weeks MDD duration and a severity score of 40 on the Children's Depression Rating Scale-Revised were required. All were scanned at 3T with MRI, multi-voxel 3-dimensional, high, 0.75 cm(3), spatial resolution proton magnetic resonance spectroscopic imaging. Striatal tCho concentrations were assessed using phantom replacement. Spearman correlation coefficients were Bonferroni-corrected.
RESULTS: Positive correlations were found only in the melancholic group, between KYN and 3-HAA and tCho in the right caudate (r=0.93, p=0.03) and the left putamen (r=0.96, p=.006), respectively.
CONCLUSIONS: These preliminary findings suggest a possible role of the KYN pathway in adolescent melancholic MDD. Larger studies should follow. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19778568      PMCID: PMC2815014          DOI: 10.1016/j.pnpbp.2009.09.015

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  52 in total

1.  Effect of windowing and zero-filled reconstruction of MRI data on spatial resolution and acquisition strategy.

Authors:  M A Bernstein; S B Fain; S J Riederer
Journal:  J Magn Reson Imaging       Date:  2001-09       Impact factor: 4.813

2.  Increased orbitofrontal cortex levels of choline in depressed adolescents as detected by in vivo proton magnetic resonance spectroscopy.

Authors:  R J Steingard; D A Yurgelun-Todd; J Hennen; J C Moore; C M Moore; K Vakili; A D Young; A Katic; W R Beardslee; P F Renshaw
Journal:  Biol Psychiatry       Date:  2000-12-01       Impact factor: 13.382

3.  Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes.

Authors:  Rejane G Tavares; Carla I Tasca; Candice E S Santos; Letícia B Alves; Lisiane O Porciúncula; Tatiana Emanuelli; Diogo O Souza
Journal:  Neurochem Int       Date:  2002-06       Impact factor: 3.921

4.  Quantitative proton magnetic resonance spectroscopy of the basal ganglia in patients with affective disorders.

Authors:  H Hamakawa; T Kato; J Murashita; N Kato
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1998       Impact factor: 5.270

5.  3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction.

Authors:  L E Goldstein; M C Leopold; X Huang; C S Atwood; A J Saunders; M Hartshorn; J T Lim; K Y Faget; J A Muffat; R C Scarpa; L T Chylack; E F Bowden; R E Tanzi; A I Bush
Journal:  Biochemistry       Date:  2000-06-20       Impact factor: 3.162

6.  An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid.

Authors:  M N Perkins; T W Stone
Journal:  Brain Res       Date:  1982-09-09       Impact factor: 3.252

7.  Kynurenine pathway in major depression: evidence of impaired neuroprotection.

Authors:  Aye-Mu Myint; Yong Ku Kim; Robert Verkerk; Simon Scharpé; Harry Steinbusch; Brian Leonard
Journal:  J Affect Disord       Date:  2006-09-06       Impact factor: 4.839

8.  Focal and lateralized subcortical abnormalities in unipolar major depressive disorder: an automated multivoxel proton magnetic resonance spectroscopy study.

Authors:  Meena Vythilingam; H Cecil Charles; Larry A Tupler; Timothy Blitchington; Lisalynn Kelly; K Ranga Rama Krishnan
Journal:  Biol Psychiatry       Date:  2003-10-01       Impact factor: 13.382

9.  Reduced caudate gray matter volume in women with major depressive disorder.

Authors:  M Justin Kim; J Paul Hamilton; Ian H Gotlib
Journal:  Psychiatry Res       Date:  2008-10-19       Impact factor: 3.222

10.  Anatomical MRI study of basal ganglia in major depressive disorder.

Authors:  Acioly L T Lacerda; Mark A Nicoletti; Paolo Brambilla; Roberto B Sassi; Alan G Mallinger; Ellen Frank; David J Kupfer; Matcheri S Keshavan; Jair C Soares
Journal:  Psychiatry Res       Date:  2003-11-30       Impact factor: 3.222

View more
  27 in total

1.  Translating progress in depression research to the clinic: one step at a time on a very long road.

Authors:  Wayne C Drevets
Journal:  World Psychiatry       Date:  2010-10       Impact factor: 49.548

Review 2.  Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies.

Authors:  Gislaine Z Réus; Karen Jansen; Stephanie Titus; André F Carvalho; Vilma Gabbay; João Quevedo
Journal:  J Psychiatr Res       Date:  2015-05-19       Impact factor: 4.791

3.  Anhedonia as a clinical correlate of inflammation in adolescents across psychiatric conditions.

Authors:  Rachel D Freed; Lushna M Mehra; Daniel Laor; Manishkumar Patel; Carmen M Alonso; Seunghee Kim-Schulze; Vilma Gabbay
Journal:  World J Biol Psychiatry       Date:  2018-08-16       Impact factor: 4.132

Review 4.  Unraveling the miswired connectome: a developmental perspective.

Authors:  Adriana Di Martino; Damien A Fair; Clare Kelly; Theodore D Satterthwaite; F Xavier Castellanos; Moriah E Thomason; R Cameron Craddock; Beatriz Luna; Bennett L Leventhal; Xi-Nian Zuo; Michael P Milham
Journal:  Neuron       Date:  2014-09-17       Impact factor: 17.173

Review 5.  The role of the kynurenine metabolism in major depression.

Authors:  Aye-Mu Myint; Markus J Schwarz; Norbert Müller
Journal:  J Neural Transm (Vienna)       Date:  2011-12-03       Impact factor: 3.575

6.  The role of the kynurenine pathway in suicidality in adolescent major depressive disorder.

Authors:  Kailyn A L Bradley; Julia A C Case; Omar Khan; Thomas Ricart; Amira Hanna; Carmen M Alonso; Vilma Gabbay
Journal:  Psychiatry Res       Date:  2015-04-01       Impact factor: 3.222

7.  A Double-Blind Placebo-Controlled Trial of Omega-3 Fatty Acids as a Monotherapy for Adolescent Depression.

Authors:  Vilma Gabbay; Rachel D Freed; Carmen M Alonso; Stefanie Senger; Jill Stadterman; Beth A Davison; Rachel G Klein
Journal:  J Clin Psychiatry       Date:  2018-06-26       Impact factor: 4.384

8.  Smaller Dentate Gyrus and CA2 and CA3 Volumes Are Associated with Kynurenine Metabolites in Collegiate Football Athletes.

Authors:  Timothy B Meier; Jonathan Savitz; Rashmi Singh; T Kent Teague; Patrick S F Bellgowan
Journal:  J Neurotrauma       Date:  2016-01-13       Impact factor: 5.269

9.  Increased ventricular cerebrospinal fluid lactate in depressed adolescents.

Authors:  K A L Bradley; X Mao; J A C Case; G Kang; D C Shungu; V Gabbay
Journal:  Eur Psychiatry       Date:  2016-01-21       Impact factor: 5.361

10.  IgA/IgM responses to tryptophan and tryptophan catabolites (TRYCATs) are differently associated with prenatal depression, physio-somatic symptoms at the end of term and premenstrual syndrome.

Authors:  Chutima Roomruangwong; Buranee Kanchanatawan; Sunee Sirivichayakul; George Anderson; André F Carvalho; Sebastien Duleu; Michel Geffard; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-04-01       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.